Elżbieta U. Stolarczyk

Dr. Elżbieta U. Stolarczyk


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ESElżbieta U. Stolarczyk
Elżbieta U. Stolarczyk
KSKrzysztof Stolarczyk
Krzysztof Stolarczyk
MŁMarta Łaszcz
Marta Łaszcz
MKMarek Kubiszewski
Marek Kubiszewski
WMWioleta Maruszak
Wioleta Maruszak
DBDorota Bryk
Dorota Bryk

10 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
ALAgnieszka Lis-Cieplak
Agnieszka Lis-Cieplak
KTKatarzyna Trześniowska
Katarzyna Trześniowska
KSKrzysztof Stolarczyk
Krzysztof Stolarczyk
ESElżbieta U. Stolarczyk
Elżbieta U. Stolarczyk
Pyrrolizidine alkaloids (PAs) are toxic compounds that occur naturally in certain plants, however, there are many secondary pathways causing PA contamination of other plants, including medicinal herbs and plant-based food products, which pose a risk of human intoxication. It is proven that chronic exposure to PAs causes serious adverse health consequences resulting from their cytotoxicity and genotoxicity. This review briefly presents PA occurrence, structures, chemistry, and toxicity, as well as a set of analytical methods. Recently developed sensitive electrochemical and chromatographic methods for the determination of PAs in honey, teas, herbs, and spices were summarized. The main strategies for improving the analytical efficiency of PA determination are related to the use of mass spectrometric (MS) detection; therefore, this review focuses on advances in MS-based methods. Raising awareness of the potential health risks associated with the presence of PAs in food and herbal medicines requires ongoing research in this area, including the development of sensitive methods for PA determination and rigorous legal regulations of PA intake from herbal products. The maximum levels of PAs in certain products are regulated by the European Commission; however, the precise knowledge about which products contain trace but significant amounts of these alkaloids is still insufficient.

1 November 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ESElżbieta U. Stolarczyk
Elżbieta U. Stolarczyk
KSKrzysztof Stolarczyk
Krzysztof Stolarczyk
MŁMarta Łaszcz
Marta Łaszcz
MKMarek Kubiszewski
Marek Kubiszewski
ALAndrzej Leś
Andrzej Leś
OMOlga Michalak
Olga Michalak
Gold nanoparticles (AuNPs) have been widely used as nanocarriers in drug delivery application. However, the binding mechanism between AuNPs and drug bases still remains a puzzle. Our study included: (i) optimization of three synthesis of the AuNPs-pemetrexed (PE) nanocomposites formation which was monitored by UV-Vis spectroscopy, (ii) identification of PE in gold nanocomposites and mechanism of PE interaction with gold nanoparticles by electrochemistry, NMR and Raman measurements, (iii) characterization of the three nanocomposites by TEM, DSL, ESL, zeta potential, XRPD and TGA analysis. The obtained nanocomposites are homogeneously shaped and have a maximum diameter of around 14nm and 88nm, as measured by the TEM and DSL techniques, respectively. The zeta potential of the nanocomposites is -43mV and suggests a high stability of the nanoparticles and lower toxicity for the normal cells. Quantum chemical calculations were also performed on model systems to estimate the strength of the AuNPs-PE interaction. Taking into account the experimental and theoretical data a mechanism of the nanocomposites' formation has been proposed in which PE interacts with the gold surface by the COOH/COO- group.

Verified
Journal Article
Open access
PDF file
AWAnna Barbara Witkowska
Anna Barbara Witkowska
JGJoanna Giebultowicz
Joanna Giebultowicz
MDMagdalena Dąbrowska
Magdalena Dąbrowska
ESElżbieta U. Stolarczyk
Elżbieta U. Stolarczyk
A worldwide crisis with nitrosamine contamination in medical products began in 2018. Therefore, trace-level analysis of nitrosamines is becoming an emerging topic of interest in the field of quality control. A novel GC-MS method with electron ionization and microextraction was developed and validated for simultaneous determination of nine carcinogenic nitrosamines (NDMA, NMEA, NDEA, NDBA, NMOR, NPYR, NPIP, NDPA, and N-methyl-npz) in active pharmaceutical ingredients (APIs): cilostazol, sunitinib malate, and olmesartan medoxomil. The method was validated according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, demonstrating good linearity in the range of LOQ up to 21.6 ng/mL (120% of specification limit). The limits of detection for the nine nitrosamines were determined to be in the range 0.15–1.00 ng/mL. The developed trace level GC-MS method turned out to be specific, accurate, and precise. The accuracy of all the tested APIs ranged from 94.09% to 111.22% and the precision evaluated by repeatability, intermediate precision, and system precision was RSD ≤ 7.65%. Nitrosamines were not detected in cilostazol and sunitinib, whereas in olmesartan medoxomil NDEA was detected at the level of LOQ. The novel protocol was successfully applied for nitrosamines determination in selected APIs and can be used for the routine quality control of APIs under Good Manufacturing Practices rules, ensuring the safety and effectiveness of pharmaceutical products.

1 June 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ESElżbieta U. Stolarczyk
Elżbieta U. Stolarczyk
ALAndrzej Leś
Andrzej Leś
MŁMarta Łaszcz
Marta Łaszcz
MKMarek Kubiszewski
Marek Kubiszewski
WSWeronika Strzempek
Weronika Strzempek
KSKrzysztof Stolarczyk
Krzysztof Stolarczyk

23 July 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
PWPiotr Wojdasiewicz
Piotr Wojdasiewicz
SBStanisław Brodacki
Stanisław Brodacki
ECEwa Cieślicka
Ewa Cieślicka
PTPaweł Turczyn
Paweł Turczyn
ŁPŁukasz A. Poniatowski
Łukasz A. Poniatowski
Dariusz SzukiewiczDariusz Szukiewicz
Dariusz Szukiewicz
Rhodiola rosea, a long-lived herbaceous plant from the Crassulaceae group, contains the active compound salidroside, recognized as an adaptogen with significant therapeutic potential for bone metabolism. Salidroside promotes osteoblast proliferation and differentiation by activating critical signaling pathways, including bone morphogenetic protein-2 and adenosine monophosphate-activated protein kinase, essential for bone formation and growth. It enhances osteogenic activity by increasing alkaline phosphatase activity and mineralization markers, while upregulating key regulatory proteins including runt-related transcription factor 2 and osterix. Additionally, salidroside facilitates angiogenesis via the hypoxia-inducible factor 1-alpha and vascular endothelial growth factor pathway, crucial for coupling bone development with vascular support. Its antioxidant properties offer protection against bone loss by reducing oxidative stress and promoting osteogenic differentiation through the nuclear factor erythroid 2-related factor 2 pathway. Salidroside has the capability to counteract the negative effects of glucocorticoids on bone cells and prevents steroid-induced osteonecrosis. Additionally, it exhibits multifaceted anti-inflammatory actions, notably through the inhibition of tumor necrosis factor-alpha and interleukin-6 expression, while enhancing the expression of interleukin-10. This publication presents a comprehensive review of the literature on the impact of salidroside on various aspects of bone tissue metabolism, emphasizing its potential role in the prevention and treatment of osteoporosis and other diseases affecting bone physiology.